Rigenerand receives regulatory approval for gene therapy production in Italy The italian biotech company Rigenerand has received received authorization from the Italian Medicine Authority (AIFA) to produce gene therapy medicinal products for clinical purposes. This approval enables Rigenerand to manufacture its own product, RR001, for the treatment of pancreatic cancer.…..
Trend Chart On Innovative Bioindustries - June 2020, 2nd FEATURE STORY ● Novartis snags EU nod for SMA gene therapy After a manufacturing-related delay, Novartis has won conditional approval in the EU for Zolgensma®, the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:"AAV-based gene therapy Products: Ongoing Clinical Trials". This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49…..
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil…..
Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for neurodegenerative disorders. Founded in 2015, BrainVectis is a spin-off from French national institute for health and medical research (INSERM). Based on work carried out by Nathalie Cartier-Lacave and her team and collaborators…..
Trend Chart on Innovative Bioindustries April 12th FEATURE STORY ● Sirnaomics releases positive interim data from phase II Trial of siRNA candidate studies Sirnaomics, a US-China RNAi therapeutics company, reported on April 9th positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705…..
FEATURE STORY ● Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies GENE THERAPY ● Permanent inactivation of HBV genomes by CRISPR/Cas9-mdediated non cleavage base editing DISRUPTIVE TECHNOLOGIES ● Hydroxybutyl chitosan centered biocomposites for potential curative applications ● CAR-T treatment for hematological malignancies ● Anti-CRISPRs :…..
Trend Chart on Orphans - February 15th, 2020 FEATURE STORY ● The potential of gene therapy for mucopolysaccharidosis type I GENE THERAPY ● Repair of retinal degeneration following ex vivo Minicircle DNA gene therapy and transplantation of corrected photoreceptor progenitors RARE DISEASES ● Genetics and other omics in pediatric pulmonary…..
Trend Chart on Innovative Biotherapies - January 15th, 2020 FEATURE STORY ● The National Gene Vector Biorepository. Eleven years of providing resources to the gene therapy community GENE THERAPY ● Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays DISRUPTIVE TECHNOLOGIES ● A small molecule-controlled Cas9 repressible system…..
Morpholino technology could allow control of gene therapy doses Scientists at Scripps Research, led by principal investigator Michael Farzan, have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing. The feat, reported in Nature Biotechnology, offers gene therapy designers what may…..